Replimune stock.

Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a …BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POST

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ... To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...

Replimune Group : The very small 0.44% REPL stake saw a ~18% increase last quarter at prices between ~$17 and ~$28. The stock is now at ~$19. The stock is now at ~$19. Note: they have a ~10% ...WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ...

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ... Replimune Group Stock Price | REPL Stock Quote, News, and History | Markets Insider The latest Replimune Group stock prices, stock quotes, news, and …About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ...

Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Report of unscheduled material events or corporate event. 8-K. 0001104659-23-115027.pdf. 0001104659-23-115027.rtf. 0001104659-23-115027.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 07, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ... Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...Fiscal Q2 2024 ended 9/30/23. Get the latest Replimune Group Inc (REPL) real-time quote, historical performance, charts, and other financial information to help you make more …Fiscal Q2 2024 ended 9/30/23. Get the latest Replimune Group Inc (REPL) real-time quote, historical performance, charts, and other financial information to help you make more …Indeed, Replimune Group (NASDAQ:REPL) stock is up 152% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all ...REPL. About Replimune Group Inc. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer ...

Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ...Replimune ( REPL) shares fell early this month after the company disclosed in its latest 10Q filing that the FDA raised certain issues related to CERPASS, including those on study endpoints, for ...Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 …Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.Replimune Group Stock Performance Shares of REPL stock opened at $11.71 on Monday. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.Stock analysis for Replimune Group Inc (REPL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ...

Replimune Group Inc. is doing cutting-edge work in the field of new cures for cancer. They are "pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the ...Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Shares of Replimune have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. ... The stock could also be impacted by negative ...Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports.Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have …14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.REPL News. This page features the latest news about the Replimune stock. Replimune earnings missed by $0.09, revenue was in line with estimates. By Investing.com. • Nov 07, 2023. Replimune ...Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short …

From the period between 2010 and 2023, Replimune, Working Capital regression line of its data series had standard deviation of 201,967,139 and standard deviation of 201,967,139. Replimune Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 191.06 Million.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy …

Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...View the latest Replimune Group Inc. (REPL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Item 1. Description of Registrant’s Securities to be Registered. A description of the common stock of Replimune Group, Inc. (the “Registrant”), par value $0.001 per share, to be registered hereunder is set forth under the caption “Description of capital stock” in the prospectus that constitutes a part of the Registrant’s Registration Statement on Form S …See Insiders’ Hot Stocks on TipRanks >> Replimune Group (REPL) Barclays analyst Peter Lawson assigned a Buy rating to Replimune Group yesterday and set a price target of $50.00.The company’s ...Dec 3, 2023 · Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last traded at $10.80. Approximately 15,578 shares traded hands during trading, a decline of 97% from the average daily volume of 618,826 shares. The stock had previously closed at $11.18. Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m... At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...

Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ... Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Nov 30, 2023 · Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ... Instagram:https://instagram. best preferred stock etfcpng stocksetf channeltop 529 plans Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ... best dividend penny stockshow much is a 1921 one dollar coin worth A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. bbb stocks Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ... Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...